| Autor: |
Drohan, W.N., Clark, D.B. |
| Zdroj: |
Journal of Animal Science; January 2000, Vol. 78 Issue: 1, Number 1 Supplement 3 p1-7, 7p |
| Abstrakt: |
Safe and effective protein concentrates produced from transgenic animals should be available in the future in relatively unlimited quantities and at reasonable costs. The technology for the production of recombinant human proteins in the milk of transgenic animals has advanced markedly in the past few years to the point where a number of therapeutically useful proteins have been produced at levels on the order of tens of grams of protein per liter of milk. Two such proteins, antithrombin III and α1-antitrypsin, are currently in clinical trials. However, a number of issues remain to be solved, including the low success rate in producing transgenic animals and differences in posttranslational processing of the expressed proteins compared to their native human counterparts. Overall, though, the future of transgenic technology for the production of recombinant human plasma proteins appears bright. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
